Kidney conditions: CKD and SGLT2 inhibitors

This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m² to 44 ml/min/1.73 m² and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m² to 59 ml/min/1.73 m², are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.

Last reviewed: 18 February 2026

This indicator updates and replaces NICE indicator 322.

Next review: February 2029

This indicator will be reviewed using the assessment criteria in appendix A of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.

How to use NICE indicators and how we develop them

Indicators can be used in a number of different settings to support high quality care. These include:

• identifying where improvements are needed
• setting priorities for quality improvement and support
• creating local performance dashboards
• benchmarking performance against national data
• supporting local quality improvement schemes
• showing progress that local health systems are making on outcomes.

Find out how to use indicators and how we develop them.